-
The total investment is 3.05 billion yuan! The foundation laying and commencement of TUL (Gaolan Port) project
On November 22, 2023, the groundbreaking ceremony for the United Laboratories (Gaolan Port) project was held in Nanshui Town, Jinwan District, Zhuhai City. More than 200 people, including leaders of the Zhuhai Municipal Government, senior executives and emplo...
Date： 2024-03-25 Browse：467
-
TUL won the "ESG Special Commendation Award"
On November 9, 2023, the TVB Environmental, Social and Governance Awards 2023 ceremony was held in Hong Kong, and The United Laboratories International Holdings Limited (3933. HK) was awarded the ESG Special Commendation Award.
Date： 2024-03-25 Browse：397
-
Chairman of the Board of Directors of TUL, Tsoi Hoi Shan, visited and exchanged ideas with Wens Group in Guangdong
On October 31, 2023, Tsoi Hoi Shan, Chairman of the Board of Directors of TUL, and Liu Hongchi, General Manager of The United Animal Healthcare (Inner Mongolia) Co., Ltd., visited and inspected the headquarters of Wens Group in Guangdong.
Date： 2024-03-25 Browse：456
-
Tsoi Hoi Shan is honored to serve as Honorary President of Jinwan Hong Kong & Macau Chamber of Commerce
On October 28, 2023, the inaugural ceremony of the first Executive Council of the Jinwan Hong Kong & Macau Chamber of Commerce was held in Hong Kong, and the Chairman of the Board of Directors of the United Laboratories, Tsoi Hoi Shan, was honored as the Hono...
Date： 2024-03-25 Browse：411
- TUL Degu and Liraglutide insulin compound preparation obtained clinical approval. Date： 2023-04-26 Browse：0
-
TUL Amoxicillin Capsules (specification: 0.5g) passed the consistency evalsuation of generic drugs
Recently, TUL obtained the Notice of Approval of Supplementary Drug Application for Amoxicillin Capsules (specification: 0.5g) approved and issued by NMPA, which approved this product to pass the quality and efficacy consistency evalsuation of generic drugs.
Date： 2023-04-26 Browse：1015
- 2022 Annual Results Announcement Date： 2023-04-20 Browse：0
-
Zhuhai United Laboratories (Zhongshan) Company Received Special Funds for Industrial Development in Zhongshan City
Date： 2024-03-25 Browse：293
Recently, Zhuhai United Laboratories (Zhongshan) Company received 1.4665 million yuan in funding for the 2023 Zhongshan Industrial Development Special Project (Technical Transformation Project).
-
TUL has won two awards
Date： 2024-03-25 Browse：267
On November 1, 2023, at the 2023 Zhongshan Entrepreneurs Conference, Zhuhai United Laboratories (Zhongshan) Company won two awards: "Outstanding Enterprise of Zhongshan City Outstanding Contribution Award" and "Top 30 Science and Technology Innovation Enterpr...
-
The product of The United Laboratories (Inner Mongolia) Co., Ltd. Taiwanmycin Tartrate, has successfully passed GMP inspection and obtained a veterinary drug production license
Date： 2024-03-25 Browse：281
From October 23rd to 24th, 2023, the expert group appointed by the Veterinary Bureau of Inner Mongolia Agriculture and Animal Husbandry Department and relevant personnel from Bayannur Agriculture and Animal Husbandry Bureau served as on-site observers to cond...
-
Tsoi Hoi Shan attends Bayannaoer Investment Promotion Symposium in Shenzhen
Date： 2023-11-01 Browse：648
On October 22nd, the Bayannaoer Municipal Government held a symposium on investment promotion in Shenzhen, with Tsoi Hoi Shan, Chairman of the Board of Directors of the United Laboratories, invited to attend. At the meeting, the government and enterprises had...
-
The United Laboratories received Special Fund for Science and Technology Innovation Development in Zhongshan City
Date： 2023-11-01 Browse：673
Recently, Zhuhai United Laboratories (Zhongshan) Company received 1 million yuan in 2023 from the second batch of Zhongshan City Enterprise Science and Technology Innovation Development Special Fund (after enterprise research and development expenses).
- Class 1 innovative drug UBT251 injection clinical trial approved by the US FDA Date： 2023-11-01 Browse：0
- Class 1 innovative drug TUL01101 tablets (indication: moderate to severe atopic dermatitis) approved for clinical trial. Date： 2023-11-01 Browse：0
- Class 1 innovative drug UBT251 injection (indication: non-alcoholic fatty liver disease) approved for clinical trial. Date： 2023-11-01 Browse：0